Neurocrine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

CEO

Kyle W. Gano

CEOKyle W. Gano

Employees

1,800

Employees1,800

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1992

Founded1992

Employees

1,800

Employees1,800

NBIX Key Statistics

Market cap

13.76B

Market cap13.76B

Price-Earnings ratio

33.11

Price-Earnings ratio33.11

Dividend yield

—

Dividend yield—

Average volume

1.06M

Average volume1.06M

High today

$142.47

High today$142.47

Low today

$137.02

Low today$137.02

Open price

$140.22

Open price$140.22

Volume

1.08M

Volume1.08M

52 Week high

$157.67

52 Week high$157.67

52 Week low

$84.23

52 Week low$84.23

Stock Snapshot

As of today, Neurocrine(NBIX) shares are valued at $138.06. The company's market cap stands at 13.76B, with a P/E ratio of 33.11.

During the trading session on 2025-11-20, Neurocrine(NBIX) shares reached a daily high of $142.47 and a low of $137.02. At a current price of $138.06, the stock is +0.8% higher than the low and still -3.1% under the high.

Trading volume for Neurocrine(NBIX) stock has reached 1.08M, versus its average volume of 1.06M.

The stock's 52-week range extends from a low of $84.23 to a high of $157.67.

Analyst ratings

90%

of 29 ratings

Buy

89.7%

Hold

10.3%

Sell

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.